You are here

Update on Dolutegravir

Thursday, May 24, 2018

TargetHIV

Interim guidance on potential neural tube birth defects associated with use of the HIV antiretroviral Dolutegravir is summarized in a May 23, 2018 Ryan White HIV/AIDS Program Colleagues letter from Dr. Laura Cheever of HRSA's HIV/AIDS Bureau.

The letter provides a recap of recommendations from three national HHS Antiretroviral Guidelines Panels as FDA continues its investigation and echoes the joint Panels May 18 statement, Statement on Potential Safety Signal in Infants Born to Women Taking Dolutegravir from the HHS Antiretroviral Guideline Panels.

Guideline Panels:

  • The Panel on Antiretroviral Guidelines for Adults and Adolescents
  • The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV
  • The Panel on Treatment of Pregnant Women Living with HIV and Prevention of Perinatal Transmission
Read the HRSA/HAB Dear Colleagues Letter
Total views: 280